The contract will apply to Highmark’s commercial insurance members in national and Pennsylvania, West Virginia and Delaware markets. Highmark said the contract marks one of the first outcomes-based agreements for a drug treating the chronic lung diseases.
Under the contract, if Highmark members who use Symbicort don’t have aligned results with clinical trials performed by AstraZeneca, the drugmaker will issue Highmark a rebate.
More articles on supply chain:
‘We can’t view ourselves as the box pushers of a hospital’: 3 experts discuss the evolving hospital supply chain
CVS Health elevates Kevin Hourican to president of CVS Pharmacy: 4 things to know
Coastal Meds recalls all drug products marketed as sterile
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
